MedTrace Logo

Research on Translational Outcomes of Alcohol (Project RETRO)

NCT04742348 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2023-02-13

No results posted yet for this study

Summary

The primary aim of the current study is to assess the effect of a single dose of carbidopa-levodopa on ad libitum alcohol consumption and alcohol craving in young adults with a history of binge drinking.

Conditions

  • Alcohol Drinking

Interventions

DRUG

Carbidopa Levodopa

Participants who are randomized to active drug group will receive 1 dose of immediate release carbidopa-levodopa (50mg/500mg) .

DRUG

Placebo

Participants who are randomized to placebo group will be provided with similar looking tablet(s) as the active drug.

Sponsors & Collaborators

Principal Investigators

  • Brittney Hultgren, PhD · University of Washington

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
24 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-02-28
Primary Completion
2023-08-31
Completion
2023-08-31
FDA Drug
Yes

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04742348 on ClinicalTrials.gov